Profile data is unavailable for this security.
About the company
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company. The Company is focused on discovering and developing medicines in the field of immunotherapy. The Company has a research and development pipeline of investigational medicines in immunology and oncology. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its pipeline includes NKTR-255, Rezpegaldesleukin (REZPEG) and NKTR-0165. NKTR-255 is an investigational biologic that is designed to target the interleukin-15 (IL-15) pathway in order to activate the body’s innate and adaptive immunity. Its Rezpegaldesleukin pipeline is an investigational, potential first-in-class T regulatory cell stimulator that addresses this underlying immune system imbalance in people with many autoimmune and inflammatory conditions. Rezpegaldesleukin is being developed as a self-administered injection.
- Revenue in USD (TTM)90.17m
- Net income in USD-175.84m
- Incorporated1998
- Employees137.00
- LocationNektar Therapeutics455 Mission Bay Boulevard SouthSAN FRANCISCO 94158United StatesUSA
- Phone+1 (415) 482-5300
- Fax+1 (415) 339-5300
- Websitehttps://www.nektar.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sanara Medtech Inc | 64.99m | -4.30m | 285.59m | 107.00 | -- | 6.31 | -- | 4.39 | -0.5219 | -0.5219 | 7.85 | 5.25 | 0.9635 | 1.90 | 8.37 | 607,381.70 | -6.58 | -17.73 | -8.17 | -22.07 | 87.92 | 88.08 | -6.83 | -17.13 | 1.04 | -18.75 | 0.1786 | -- | 41.77 | 61.93 | 45.79 | -- | 99.09 | -- |
| Fibrobiologics Inc | 0.00 | -19.06m | 285.97m | 10.00 | -- | 227.63 | -- | -- | -0.9149 | -0.9149 | 0.00 | 0.0384 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -60.47 | 0.1012 | -- | -- | -- | -272.15 | -- | -- | -- |
| Inozyme Pharma Inc | 0.00 | -77.11m | 287.24m | 59.00 | -- | 2.42 | -- | -- | -1.37 | -1.37 | 0.00 | 1.92 | 0.00 | -- | -- | 0.00 | -48.39 | -45.00 | -52.50 | -48.90 | -- | -- | -- | -- | -- | -- | 0.2748 | -- | -- | -- | -6.13 | -- | 2.85 | -- |
| Invivyd Inc | 0.00 | -198.64m | 288.52m | 94.00 | -- | 1.50 | -- | -- | -1.81 | -1.81 | 0.00 | 1.61 | 0.00 | -- | -- | 0.00 | -64.88 | -- | -73.98 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 17.68 | -- | -- | -- |
| Adaptimmune Therapeutics PLC - ADR | 60.28m | -113.87m | 291.34m | 449.00 | -- | 6.55 | -- | 4.83 | -0.5218 | -0.5218 | 0.2995 | 0.1739 | 0.1972 | -- | 14.60 | 134,256.10 | -37.24 | -41.19 | -48.02 | -48.21 | -- | -- | -188.90 | -714.26 | -- | -- | 0.00 | -- | 122.05 | 0.2595 | 31.18 | -- | 0.7202 | -- |
| Vanda Pharmaceuticals Inc. | 192.64m | 2.51m | 291.57m | 203.00 | 114.25 | 0.529 | 52.83 | 1.51 | 0.0439 | 0.0439 | 3.35 | 9.47 | 0.3004 | 11.60 | 5.69 | 948,965.50 | 0.3912 | 6.61 | 0.4547 | 7.62 | 92.32 | 90.55 | 1.30 | 15.18 | 4.92 | -- | 0.00 | 0.00 | -24.27 | -0.0496 | -60.02 | -36.96 | -56.77 | -- |
| Candel Therapeutics Inc | 0.00 | -37.94m | 292.59m | 42.00 | -- | 22.76 | -- | -- | -1.31 | -1.31 | 0.00 | 0.4381 | 0.00 | -- | -- | 0.00 | -63.82 | -- | -76.57 | -- | -- | -- | -- | -- | -- | -73.91 | 0.6254 | -- | -100.00 | -- | -101.87 | -- | -- | -- |
| Zura Bio Ltd | 0.00 | -69.24m | 292.95m | 14.00 | -- | 3.38 | -- | -- | -4.38 | -4.38 | 0.00 | 1.36 | 0.00 | -- | -- | 0.00 | -49.98 | -- | -60.56 | -- | -- | -- | -- | -- | -- | -- | 0.0123 | -- | -- | -- | -2,050.99 | -- | -- | -- |
| Nektar Therapeutics | 90.17m | -175.84m | 293.80m | 137.00 | -- | 2.32 | -- | 3.26 | -0.9195 | -0.9195 | 0.4709 | 0.6901 | 0.1883 | 1.93 | 27.27 | 658,153.30 | -36.72 | -31.02 | -41.60 | -34.63 | 60.91 | 78.04 | -195.02 | -372.21 | 5.79 | -24.95 | -- | -- | -2.10 | -40.35 | 25.03 | -- | -42.89 | -- |
| Nature's Sunshine Products Inc | 447.68m | 16.54m | 293.95m | 814.00 | 18.42 | 1.90 | 9.86 | 0.6566 | 0.8479 | 0.8479 | 22.96 | 8.20 | 1.86 | 1.91 | 44.39 | 549,974.20 | 7.33 | 6.57 | 10.66 | 9.41 | 72.19 | 72.69 | 3.94 | 3.74 | 1.42 | -- | 0.013 | 27.72 | 5.55 | 4.07 | 3,965.64 | -- | 16.73 | -- |
| CorMedix Inc | 0.00 | -50.24m | 297.45m | 82.00 | -- | 5.13 | -- | -- | -0.9291 | -0.9291 | 0.00 | 1.06 | 0.00 | -- | -- | 0.00 | -78.96 | -54.84 | -88.88 | -62.32 | -- | 6.18 | -- | -18,323.42 | 6.41 | -- | 0.00 | -- | -100.00 | -- | -56.02 | -- | 46.27 | -- |
| Fractyl Health Inc | 120.00k | -94.27m | 297.80m | 102.00 | -- | -- | -- | 2,481.69 | -1.97 | -1.97 | 0.0025 | -0.7881 | -- | -- | -- | 1,176.47 | -- | -- | -- | -- | 35.83 | -- | -64,242.50 | -- | 3.18 | -2.62 | 3.17 | -- | -- | -- | -48.15 | -- | -- | -- |
| Aquestive Therapeutics Inc | 51.50m | -28.77m | 299.52m | 135.00 | -- | -- | -- | 5.82 | -0.4273 | -0.4273 | 0.7836 | -0.4012 | 0.5398 | 2.78 | 6.49 | 381,496.30 | -30.15 | -76.63 | -43.46 | -123.85 | 60.23 | 64.24 | -55.85 | -102.95 | 5.85 | -3.51 | -- | -- | 6.09 | -5.59 | 85.54 | -- | -11.42 | -- |
| Mersana Therapeutics Inc | 38.30m | -134.81m | 301.62m | 123.00 | -- | 10.78 | -- | 7.88 | -1.14 | -1.14 | 0.3203 | 0.2287 | 0.1549 | -- | -- | 311,365.80 | -54.52 | -61.68 | -75.37 | -81.35 | -- | -- | -352.01 | -622.19 | -- | -- | 0.4749 | -- | 38.65 | 28.32 | 15.94 | -- | 9.61 | -- |
| Verastem Inc | -100.00bn | -100.00bn | 301.67m | 73.00 | -- | 12.04 | -- | -- | -- | -- | -- | 0.9903 | -- | -- | -- | -- | -- | -62.70 | -- | -75.18 | -- | -- | -- | -406.17 | -- | -- | 0.6208 | -- | -100.00 | -- | -18.36 | -- | -- | -- |
| Organogenesis Holdings Inc | 433.14m | 4.95m | 302.27m | 862.00 | 62.02 | 1.07 | 14.88 | 0.6979 | 0.0368 | 0.0368 | 3.27 | 2.12 | 0.9526 | 4.02 | 5.05 | 502,482.60 | 1.09 | 5.46 | 1.31 | 6.90 | 75.42 | 74.94 | 1.14 | 4.81 | 2.44 | 9.05 | 0.1989 | 0.00 | -3.94 | 17.49 | -68.16 | -- | 67.34 | -- |
Data as of May 09 2024. Currency figures normalised to Nektar Therapeutics's reporting currency: US Dollar USD
40.24%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Deep Track Capital LPas of 05 Mar 2024 | 18.40m | 10.02% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 11.97m | 6.52% |
| Acadian Asset Management LLCas of 31 Dec 2023 | 7.82m | 4.26% |
| PRIMECAP Management Co.as of 31 Dec 2023 | 7.00m | 3.81% |
| Monaco Asset Management SAMas of 31 Dec 2023 | 5.97m | 3.25% |
| Citadel Advisors LLCas of 31 Dec 2023 | 5.63m | 3.06% |
| Renaissance Technologies LLCas of 31 Dec 2023 | 5.33m | 2.90% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 4.15m | 2.26% |
| D. E. Shaw & Co. LPas of 31 Dec 2023 | 4.10m | 2.23% |
| Alyeska Investment Group LPas of 31 Dec 2023 | 3.52m | 1.92% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
